A comparison of the effects of nine folate analogs on early and late murine hematopoietic progenitor cells in vitro

Cancer Chemotherapy and Pharmacology

Volumn 45, Issue 6, 2000, Pages 450-456

  Strømhaug, Astrid ^a   Warren, David J ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Antifolates; Colony forming units in culture; High proliferative potential colony forming cell

Indexed keywords

2 DESAMINO 2 METHYL 5,8 DIDEAZAISOFOLIC ACID; 5,8 DIDEAZAISOFOLIC ACID; AMINOPTERIN; EDATREXATE; FOLIC ACID ANTAGONIST; LOMETREXOL; METHOTREXATE; NOLATREXED; RALTITREXED; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 3; THYMIDYLATE SYNTHASE INHIBITOR; TRIMETREXATE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; CELL PROLIFERATION; COLONY FORMING CELL; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0034108035     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800051018     Document Type: Article

References (32)

1. 1. Appelt K, Bacquet RJ, Bartlett CA, Booth CLJ, Freer ST, Fuhry MAM, Gehring MR, Herrmann SM, Howland EF, Janson CA, Jones TR, Kan CC, Kathardekar V, Lewis KK, Marzoni GP, Matthews DA, Mohr C, Moomaw EW, Morse CA, Oatley SJ, Ogden RC, Reddy MR, Reich SH, Schoettlin WS, Smith WW, Varney MD, Villafranca JE, Ward RW, Webber S, Webber SE, Welsh KM, White J (1991) Design of enzyme inhibitors using iterative protein crystallographic analysis. J Med Chem 34: 1925
2. 2. Brigle KE, Spinella MJ, Westin EH, Goldman ID (1994) Increased expression and characterization of two distinct folate binding proteins in murine erythroleukemia cells. Biochem Pharmacol 47: 337
3. 3. Fernandes DJ, Bertino JR, Hynes JB (1983) Biochemical and antitumor effects of 5,8-dideazaisopteroylglutamate, a unique quinazoline inhibitor of thymidylate synthase. Cancer Res 43: 1117
4. 4. Fleming GF, Schilsky RL (1992) Antifolates: the next generation. Semin Oncol 19: 707
5. 5. Grant SC, Kris MG, Young CW, Sirotnak FM (1993) Edatrexate, an antifolate with antitumor activity: a review. Cancer Invest 11: 36
6. 6. Hagan RL, Duch DS, Smith GK, Hanlon MH, Shane B, Freisheim JH, Hynes JB (1991) Studies on the mechanism of antitumor action of 2-desamino-2-methyl-5,8-dideazaisofolic acid. Biochem Pharmacol 41: 781
7. 7. Hynes JB, Yang YCS, McGill JE, Harmon SJ, Washtien WL (1984) Improved synthesis and antitumor evaluation of 5,8-dideazaisofolic acid and closely related analogues. J Med Chem 27: 232
8. 8. Hynes JB, Smith AB, Gale GR (1986) Effects of 5,8-dideazaisopteroylglutamate (IAHQ) on L1210 leukemia in mice when given alone and in combination with methotrexate, probenecid, or verapamil. Cancer Chemother Pharmacol 18: 231
9. 9. Hynes JB, Patil AA, Hagann RL, Cole A, Kohler W, Freisheim JH (1989) Comparison of the biological effects of selected 5,8-dideazafolate analogues with their 2-desamino counterparts. J Med Chem 32: 852
10. 10. Jackman AL, Gibson W (1995) Polyglutamation of the thymidylate synthase (TS) inhibitor, ZD1694 (raltitrexed), in normal mouse tissues (abstract). Proc Am Assoc Cancer Res 36: 377
11. 11. Jackman AL, Taylor GA, Gibson W, Kimbell R, Brown M, Calvert AH, Judson IR, Hughes LR (1991) ICI S1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. Cancer Res 51: 5579
12. 12. Jansen G, Westerhof GR, Kathmann I, Rijksen G, Schornagel JH (1991) Growth-inhibitory effects of 5, 10-dideazatetrahydrofolic acid on variant murine L1210 and human CCRF-CEM leukemia cells with different membrane-transport characteristics for (anti)folate compounds. Cancer Chemother Pharmacol 28: 115
13. 13. Kamen B (1997) Folate and antifolate pharmacology. Semin Oncol 24: 30
14. 14. Matherley LH, Seither RL, Goldman ID (1994) The basis for antifolate cytotoxicity, selectivity and metabolic transformations: effects on utilization of endogenous and exogenous folate cofactors. In: Powis G (ed) Anticancer drugs: antimetabolite metabolism and natural anticancer agents. Pergamon Press, Oxford, UK, p 139
15. 15. McGuire JJ, Sobrero AF, Hynes JB, Bertino JR (1987) Mechanism of action of 5,8-dideazaisofolic acid and other quinazoline antifolates in human colon carcinoma cells. Cancer Res 47: 5975
16. 16. Moore MAS (1991) Clinical implications of positive and negative hematopoietic stem cell regulators. Blood 78: 1
17. 17. Moran RG, Baldwin SW, Taylor EC, Shih C (1989) The 6S-and 6R-diastereomers of 5, 10-dideaza-5,6,7,8-tetrahydrofolate are equiactive inhibitors of de novo purine synthesis. J Biol Chem 264: 21047
18. 18. Nelson R, Butler F, Dugan Jr W, Davisland C, Stone M, Dyke R (1990) Phase I clinical trial of LY264618 (dideazatetrahdrofolic acid; DDATHF; abstract). Proc Am Soc Clin Oncol 9: 76
19. 19. Pannacciulli I, Massa G, Bogliolo G, Ohio R, Sobrero A (1982) Effects of high-dose methotrexate and leucovorin on murine hemopoietic stem cells. Cancer Res 42: 530
20. 20. Pinedo HM, Chabner BA, Zaharko DS, Bull JM (1976) Evidence for early recruitment of granulocyte precursors during high-dose methotrexate infusions in mice. Blood 48: 301
21. 21. Pinedo HM, Zaharko DS, Bull J, Chabner BA (1977) The relative contribution of drug concentration and duration of exposure to mouse bone marrow toxicity during continuous methotrexate infusion. Cancer Res 37: 445
22. 22. Ray MS, Muggia FM, Leichman G, Grunberg SM, Nelson RL, Dyke RW, Moran RG (1993) Phase I study of (6R)-5, 10-dideazatetrahydrofolate: a folate antimetabolite inhibitory to de novo purine synthesis. J Natl Cancer Inst 85: 1154
23. 23. Sessa C, Gumbrell L, Hatty S, Cavali F (1990) Phase I study of 5, 10-dideazatetrahydrofolic acid (Ly264618; DDATHF) given daily for 3 consecutive days (abstract). Ann Oncol 1: 38
24. 24. Sessa C, Erba E, Sen S, Damia G, Cavalli F, Schmitt H, D'Incalci M, Giovanni OS, Bellinzona CH (1992) Folinic acid modulation of 5, 10-dideazatetrahydrofolic acid (DDATHF, lometrexol) cytotoxicity. Proc Am Assoc Cancer Res 33: 414
25. 25. Schmitz JC, Grindey GB, Schultz RM, Priest DG (1994) Impact of dietary folic acid on reduced folates in mouse plasma and tissues. Biochem Pharmacol 48: 319
26. 26. Strømhaug A, Slørdal L, Warren DJ (1996) Differential effects of the antifolates methotrexate, aminopterin and trimetrexate on murine hematopoietic progenitor cells. Br J Haematol 92: 514
27. 27. Sobrero AF, McGuire JJ, Bertino JR (1988) Uptake and metabolism of 5,8-dideazaisofolic acid in human colon carcinoma cells. Biochem Pharmacol 37: 997
28. 28. Takimoto CH (1997) Antifolates in clinical development. Semin Oncol 24: 40
29. 29. Touroutoglou N, Pazdur R (1996) Thymidylate synthase inhibitors. Clin Cancer Res 2: 227
30. 30. Tsang KY, Hynes JB, Fudenberg HH (1982) Effects of 5,8-dideazaisofolic acid (IAHQ) on human tumor cells in culture and on normal and tumor-bearing hamsters. Exp Chemother 28: 276
31. 31. Vogler R, Mingioli ES, Garwood FA (1973) The effect of methotrexate on granulocytic stem cells and granulopoiesis. Cancer Res 33: 1628
32. 32. Webber S, Bartlett CA, Boritzki TJ, Hilliard JA, Howland EF, Johnston AL, Kosa M, Margosiak A, Morse CA, Shetty BV (1996) AG337, a novel lipophilic thymidylate synthase inhibitor: in vitro and in vivo preclinical studies. Cancer Chemother Pharmacol 37: 509